Afatinib ≥98%|CAS:|5 mg|10 mg|25 mg

BIBW 2992|Afatanib is an anticancer chemotherapeutic compound that has been approved to treat advanced lung cancers such as non-small cell lung cancer (NSCLC) and is in clinical trials as a potential treatment for other advanced solid tumors such as breast cancer and colorectal cancer. Afatanib exerts its anticancer activity through inhibition of EGFR and EGRF2 (HER2/ErbB2). In vivo, afatanib downregulates expression of HER2, increasing apoptosis and decreasing tumor size.|C24H25ClFN5O3|485.94|Pale Yellow Powder|+4°C|